Stocks
Valneva SEVALN
NASDAQHealthcareBiotechnology$5.26
Price as of · delayed, not real-time
A pure-play vaccine developer with a commercial product for Japanese encephalitis and a partnered Lyme disease vaccine in late-stage trials. Investors track Valneva for its exposure to infectious disease R&D and its chikungunya vaccine, which received U.S. approval in 2023. The company's revenue mix includes product sales, licensing, and government contracts.
52W Range: $4.75-$12.18
Congressional Interest in Valneva SE (VALN)
No congressional trades have been disclosed for Valneva SE (VALN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading VALN?
No congressional trades found for this stock.